. Tumour cells existing under hypoxia may be more resistant to therapy for a variety of reasons. These factors include: the requirement for molecular oxygen in the fixation of radiation-induced radicals and drug-induced damage, and certain drug activation processes; non-cycling cell kinetics; and decreased drug uptake (Workman, 1991 Nitroimidazoles, including misonidazole, have been under evaluation as potential diagnostic probes for hypoxic cells. This is because of the specific reductive metabolism of the drugs to reactive metabolites which bind to macromolecules within hypoxic cells (Miller et al., 1982; Chapman et al., 1983) . The characteristics of binding have been evaluated in various cell lines and tumours, although the exact nature of the metabolite is not known (Miller et al., 1982; Chapman et al., 1983) . Interestingly, previous subcellular fractionation studies in EMT6 cells with ['4C]misonidazole have indicated that 77% and 23% of the total activity is associated with the acid-insoluble (bound) and the acid-soluble fractions (unbound) respectively (Miller et al., 1982) . Further, the acidinsoluble fraction is distributed among RNA (17%), DNA (1%), lipid (4%) and protein (1%) (Miller et al., 1982) . In another study by the Edmonton group, the involvement of intracellular enzymes in the activation process was implicated, since the temperature dependence of this process showed an activation energy of 33.5 kcal mol' (Chapman et al., 1983 al., 1992, 1993). Briefly, the technique relies upon measurement of the electron energy distribution of transmitted electrons that have lost energy following interaction with a specimen. This is done by recording an energy spectrum as a sequence of images with high spatial resolution. These filtered electron image sequences contain information about the elementspecific energy loss population (equivalent to energy loss edge) superimposed on the non-specific energy loss population (equivalent to background). Data are processed mathematically to obtain edge intensity information which relates directly to the elemental concentration of the specimen. ComCorrespondence: AD Lewis
Summary The novel fluorinated 2-nitroimidazole SR-4554 is undergoing preclinical development as a magnetic resonance spectroscopy and imaging probe for hypoxic tumour cells. We have used electron energy loss spectroscopic analysis (EELS) to show selective reduction and differential subcellular localisation of SR-4554 in human ovarian multicellular spheroids. SR-4554 was demonstrated to be metabolised by these A2780 cells under hypoxic but not under normal aerobic cell culture conditions. The EELS technique illustrated that the relative amount of drug within the cytoplasm of cells from both the inner region (150-160 gm from edge) and outer edge of the spheroid did not differ significantly after an initial 3 h incubation with drug. In contrast, an 8-fold differential between the amount of drug retained in the cytoplasm (primarily ribosomes and endoplasmic reticulum) of cells from the inner vs outer regions of the spheroids was observed following a subsequent 2 h 'chase' culture in drug-free medium. Within cells from the hypoxic region of the spheroid, SR-4554 was mainly associated with the endoplasmic reticulum, nucleus and the cytoplasmic side of intracellular vesicles and also to a lesser extent with the nuclear periphery. Interestingly, the drug was only weakly associated with the mitochondria and plasma membrane of the cells. The characteristics of cellular and subcellular distribution of SR-4554 are consistent with the hypothesis that 2-nitroimidazole compounds undergo hypoxia-mediated enzymatic reduction to reactive species. These reactive species are selectively retained in the cells in which they are metabolised through covalent association with subcellular components. These findings provide additional support for the clinical development of the drug as a non-invasive probe for tumour hypoxia and at the same time illustrate the utility of the EELS technique for examining the heterogeneity of drug distribution both between and within cells.
Keywords: electron energy loss spectroscopy; fluorinated 2-nitroimidazole; hypoxia probe Human and animal tumours have been reported to contain regions of low oxygen tension or hypoxia (Thomlinson and Gray, 1955; Moulder and Rockwell, 1984; Rampling et al., 1994) . Tumour cells existing under hypoxia may be more resistant to therapy for a variety of reasons. These factors include: the requirement for molecular oxygen in the fixation of radiation-induced radicals and drug-induced damage, and certain drug activation processes; non-cycling cell kinetics; and decreased drug uptake (Workman, 1991) . In recent years strategies have been developed to identify hypoxic cells within tumours, in order to facilitate the rational selection of appropriate therapeutic regimens. In this regard, both surgically invasive and non-invasive techniques such as autoradiography, immunohistochemistry, magnetic resonance spectroscopy (MRS) and single positron emission tomography (SPET) have been used to provide a clinically relevant approach to identifying these hypoxic cells within tumours (Chapman, 1984; Maxwell et al., 1988; Koh et al., 1991; Kwock et al., 1992; Lord et al., 1993; Hodgkiss et al., 1994; Raleigh et al., 1994) .
Nitroimidazoles, including misonidazole, have been under evaluation as potential diagnostic probes for hypoxic cells. This is because of the specific reductive metabolism of the drugs to reactive metabolites which bind to macromolecules within hypoxic cells (Miller et al., 1982; Chapman et al., 1983) . The characteristics of binding have been evaluated in various cell lines and tumours, although the exact nature of the metabolite is not known (Miller et al., 1982; Chapman et al., 1983) . Interestingly, previous subcellular fractionation studies in EMT6 cells with ['4C]misonidazole have indicated that 77% and 23% of the total activity is associated with the acid-insoluble (bound) and the acid-soluble fractions (unbound) respectively (Miller et al., 1982) . Further, the acidinsoluble fraction is distributed among RNA (17%), DNA (1%), lipid (4%) and protein (1%) (Miller et al., 1982) . In another study by the Edmonton group, the involvement of intracellular enzymes in the activation process was implicated, since the temperature dependence of this process showed an activation energy of 33.5 kcal mol' (Chapman et al., 1983) . This al., 1992, 1993) . Briefly, the technique relies upon measurement of the electron energy distribution of transmitted electrons that have lost energy following interaction with a specimen. This is done by recording an energy spectrum as a sequence of images with high spatial resolution. These filtered electron image sequences contain information about the elementspecific energy loss population (equivalent to energy loss edge) superimposed on the non-specific energy loss population (equivalent to background). Data are processed mathematically to obtain edge intensity information which relates directly to the elemental concentration of the specimen. Com- paring the intensity of two elements, as performed in our study, can thus disclose semiquantitative elemental information on a local (nm) scale.
In the present investigation, we used energy electron loss spectroscopy to study the localisation of a novel fluorinated 2-nitroimidazole SR-4554 (Figure 1 ) within A2780 human ovarian multicellular spheroids. The A2780 spheroid model was chosen because it provides the coexistence of both aerobic and hypoxic cells under normal aerobic cell culture conditions, allowing manipulations on both types of cells to be carried out simultaneously. Moreover, we have previously used this spheroid model with EELS (Huxham et al., 1992 (Huxham et al., , 1993 to assess the localisation of fluorine-containing drug bound to macromolecules within different cell populations and subcellular compartments. SR-4554 was designed to contain three equivalent fluorines within *a metabolically stable side-chain of appropriate lipophilicity, while retaining a similar reduction potential to misonidazole. Currently, SR-4554 is undergoing preclinical evaluation as a non-invasive probe for tumour hypoxia by fluorine-based magnetic resonance spectroscopy (MRS) and imaging (MRI). Together with bioreductive metabolism studies which are reported here, the present localisation studies will help in our understanding of the characteristics of metabolism-induced binding of SR-4554 and of 2-nitroimidazoles in general.
Materials and methods
Metabolism studies [N-(2-hydroxy-3,3,3 trifluoropropyl)-2-(2-nitro-1-imidazolyl) acetamide] was synthesised and supplied by SRI International, Menlo Park, CA, USA. A2780 cells were cultured as monolayers in RPMI medium (Life Technology, Paisley UK) supplemented with 10% (v/v) fetal calf serum (Globepharm, Esher, Sussex, UK), and 0.001% (w/v) insulin (Lewes, Sussex, UK). The cells were grown to near confluence, trypsinised and plated at a concentration of 5 x 10 cells ml-' in 5 ml. Cells were allowed to adhere to the flasks and the medium replaced with one containing 10 and 20"lM SR-4554. The flasks were then incubated for various lengths of time up to 3 h under hypoxic (98% nitrogen and 2% carbon dioxide) or aerobic (2% carbon dioxide and 20% oxygen in nitrogen) conditions. Drug-containing media obtained at 0, 0.5, 1, 2, 3 h were then analysed by highperformance liquid chromatography (HPLC). Localisation of a 2-nitroimWdazole hypoxia probe in human spheroids EO Aboagye et al ! 313 phase consisting of 15% methanol and water. The analytes were eluted at a flow rate of 2 ml min -', and the column effluent monitored at a wavelength of 324 nm. Franko et al., 1992) . The spheroids were incubated with culture medium containing a non-toxic concentration of 1 mM SR-4554 at 37°C for 3 h. Incubations were carried out under normal aerobic cell culture conditions. Half of the spheroids were then transferred onto ice to stop further reaction. The other half were washed with fresh culture medium and 'chased' at 37°C for 2 h under normal aerobic conditions. These were also transferred onto ice to stop further reaction.
For analytical electron microscopy, all spheroids were briefly washed in phosphate-buffered saline (PBS), and chemically fixed (on ice) with 1% glutaraldehyde in PBS for 1.5 h. The spheroids were dehydrated in a series of alcohols for embedding at low temperature in Lowicryl K4M, a nitrogen-free hydrophilic methacrylate resin, without the use of heavy metal stains to avoid electron scattering. Ultrathin sections were mounted onto 700 mesh copper grids for electron spectroscopic analysis using a Zeiss TEM902 microscope (Karl Zeiss Oberkochen, Oberkochen, Germany) operating at 80 kV and 12 000 x magnification. The microscope was fitted with an electron energy filter for analysis of the local electron energy associated with fluorine (K-edge onset at AE = 688 eV) and nitrogen (K-edge onset at AE = 405 eV). This novel technique has a resolution of about 2 nm and an energy resolution of about 5eV (Huxham et al., 1992; Johnson et al., 1995) for sections of resin-embedded cells, and a theoretical detection limit for fluorine of about 500 atoms.
Energy eV portion of the post-ionisation edge for fluorine and nitrogen were used to calculate elemental ratios. In this way, variations in the density of cellular material between one domain and another could be normalised as a function of the nitrogen content for each region of interest, to produce local semiquantitative elemental maps. Data were also expressed as Localisaffon of a 2-nitrolmidazole hypoxia probe in human spheroids EO Aboagye et al reference image on the display screen. The same ROI was used for analysis of both nitrogen and fluorine ESIS sequences. The energy losses for nitrogen and fluorine were then determined by plotting the cumulative grey level value for the ROI for each ESIS. A representative projected distribution of fluorine (green) within a section of the inner region of the spheroid after the 'chase' process is shown in Figure 4 . This represents residual bound drug within the cell. An analysis of cytoplasmic domains (which includes cytoplasm, mitochondria, vesicle periphery and plasma membrane regions) of cells within A2780 spheroids (Figure 5 ) suggest that the drug was distributed into cells across the whole spheroid after a 3 h culture. Following chemical fixation of these spheroids, only marginally less drug was bound to intracellular components within cells of the inner region of the spheroid as compared with the equivalent components of cells in the outer region. More importantly, an 8-fold higher level of drug was present within the cytoplasmic domains of these inner cells after 'chasing' with drug-free media, as most of the drug which was present in the outer cells had diffused Localisation of a 2-nitroimidazole hypoxia probe in human spheroids EQ Aboagye et al away following the 'chase' process. This selective retention of drug by the inner cells is indicative of increased bioactivation within the inner cells of the spheroids. Table II demonstrates that the drug distribution present within the cells from both the inner and outer regions of 'chased' spheroids was not uniform. Relative to the intrinsic nitrogen content of specific intracellular regions, which takes into account local variations in biological material, the amount of drug within the inner cells was found to be comparatively high at the periphery of intracellular vesicles, within the cytoplasm, in the nucleus and at its periphery. In contrast, the amount of drug was comparatively low within mitochondria and at the plasma membrane. Although the nitrogen atoms in the drug will contribute to the total nitrogen intensity signal of the EELS technique, by far the greater contribution will come from the biological macromolecules of the cell to which the drug is localised. When simply expressed in terms of the average amount of fluorine per unit area of cell section, the data suggested that there was a relative accumulation of fluorine at the nuclear periphery and in the nucleus compared with other regions, more representative of the projected fluorine distribution shown in Figure 4 . In contrast, and as expected, across all domains there was less drug (3 to 10-fold) localised within the outer cells than in the inner cells. Histograms showing the mean ± s.d. of fluorine/ nitrogen (F/N) elemental ratios for cytoplasmic domains (which includes cytoplasm, mitochondria, vesicle periphery and plasma membrane regions) from the outer and inner cells of A2780 multicellular spheroids cultured for 3 h (O) in SR-4554 and after a 2 h 'chase' culture (0) in drug-free media. Using the Mann-Whitney U-test (non-parametric), a significant difference was determined between the outer and inner cells after the 'chase' period (P < = 0.05).
Discussion
The localisation of 2-nitroimidazoles following reduction by tumour cells is important in our understanding of the use of these compounds as hypoxic probes. The human ovarian A2780 cell line was used in this study since this cell line has previously been shown to express cytochrome P450 reductase, an enzyme involved in the reductive metabolism of 2-nitroimidazoles, by enzyme assay and PCR analysis (data not shown). This cell line was also considered likely to develop a hypoxic region in spheroids over the size range used.
The characteristics of the metabolism-induced binding of 2-nitroimidazoles to macromolecules in hypoxic tissue are still not fully understood. In particular, the nature of the drug adducts and the subcellular localisation of these compounds has been poorly addressed in the literature to date. This paper addresses some of these issues with respect to the use of a novel fluorinated 2-nitroimidazole (SR-4554) in A2780 cells/spheroids and the application of the EELS technique. However, these results are also relevant to the action of other 2-nitroimidazoles. The structure of SR-4554 is based on that of etanidazole (Brown and Workman, 1980) (Miller et al., 1982; Lord et al., 1993) . In contrast to these other methods, the EELS technique also has the ability to measure drug binding relation to the density of other local macromolecular components. Although some non-specific binding occurred in the cells of the outer (aerobic) region of the spheroids, levels of fluorine in the cytoplasm of cells from the inner (hypoxic) regions were 8-fold higher. This effect is the more likely to occur in vivo, where elimination processes will result in the removal of unbound drug compared with the bound metabolite. Importantly, the localisation characteristics shown in our study are very relevant to the use of this novel fluorinated compound as a non-invasive marker of tumour hypoxia in the clinic. The presence of three magnetically equivalent fluorine atoms in the structure of the compound, which remains intact on enzyme reduction, is important in terms of its detection by resonance techniques as well as by EELS. Further studies using EELS enabled us to analyse in more detail the subcellular localisation of the compound within cells of both the outer and inner region of the spheroid. In our study, the mitochondria and plasma membrane did not appear to bind significant amounts of drug. Of interest, however, were the high levels of the compound localised to the nuclear periphery, nucleus and cytoplasm within the inner' cells. These data are in agreement with previous published studies using subcellular fractionation of cells labelled with ['4C]misonidazole (Miller et al., 1982) , considering that the molecular components in these regions consist mainly of RNA, DNA, lipids and proteins. In addition, the distribution of 2-nitroimidazole to cytoplasm, nuclear and perinuclear regions was also mentioned by Cline et al. (1994) , who used antibodies against CCI-103F/CCI-103F adducts to follow the distribution of hypoxia and/or reductive enzymes within cells of canine tumours. In contrast, and as expected, less drug was distributed within all the domains in the outer cells.
The initial steps in the reductive metabolism of 2-nitroimidazoles are mainly catalysed by cytochrome P450 reductase and to a lesser extent cytochrome P450, both of which are found in the endoplasmic reticulum (McManus et al., 1982; Walton and Workman, 1987) . The subcellular distribution of the SR-4554 compound demonstrated in our study suggests that the reactive intermediate is short-lived and binds to macromolecules within the vicinity of the metabolism site or to nucleophiles such as RNA close to these sites. Importantly, the evidence would suggest that the reactive metabolites do not appear to migrate out of the cells. This characteristic is also relevant to the design of bioreductive drugs, based on 2-nitroimidazoles, which will target the nucleus of the cell to deliver radioisotopes or alkylating moieties.
Currently, SR-4554 is undergoing preclinical development before scheduled clinical trials as a probe for investigating tumour hypoxia by non-invasive MRS. Important to the direction of these studies, this paper describes the intracellular distribution of the compound within hypoxic regions of human ovarian carcinoma spheroids and is useful in the interpretation of data from MRS studies. In addition, however, the EELS technique itself can also be used to study the distribution of hypoxic regions within tumours labelled in vivo with SR-4554, even though this will involve invasive (biopsy) procedures. As a semiquantitative technique, moreover, it offers the potential of measuring hypoxia on a cell-to-cell basis at a molecular level with good resolution compared with antibody techniques and also the investigation of drug to macromolecule interactions without the use of radioisotopes.
